Clinical Trial Update: Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial evaluating elranatamab in adults with relapsed or refractory AL amyloidosis (Phase 1/2); currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Al Amyloidosis

Drugs mentioned

• Elranatamab (elranatamab)

Snippet

Sponsor: Brigham and Women's Hospital | Conditions: AL Amyloidosis | Phase 1, Phase 2 | Status: RECRUITING